Raoult's request for extensive use of hydroxychloroquine rejected

Didier Raoult in September 2020 -

It's no.

This Friday, the national security and drug agency (ANSM) refused a request from Marseille professor Didier Raoult to use hydroxychloroquine more widely to treat the coronavirus within the IHU.

Professor Didier Raoult wanted to be able to benefit from a temporary recommendation for use (RTU), which gives access to reimbursement and aims for a prescription without massive marketing authorization, beyond the prescription on a case-by-case basis.

A request justified by the fact that the IHU of Marseille has a large number of patients.

The ANSM doubts the effectiveness of this treatment

"To date, the available data, which are very heterogeneous and uneven, do not allow us to predict a benefit from hydroxychloroquine, alone or in combination, for the treatment or prevention of Covid-19 disease", argues the ANSM in an information point posted on its website.

Our file on Covid-19

"In this context and in view of the available safety data showing increased risks, in particular cardiovascular risks, a favorable benefit / risk ratio cannot be assumed for hydroxychloroquine whatever its context of use", justifies the agency.

The ANSM also publishes an eight-page letter sent to the Marseille microbiologist, in response to his request.

The health agency specifies that "this position could be revised" if it was provided with new convincing clinical studies.

Culture

Fabrice Luchini would like to play Didier Raoult in a film biopic

Health

Coronavirus: Chloroquine, tests, virus mutation ... How Didier Raoult defended his strategy before the Senate committee

• Marseilles

• Covid 19

• Drug

• Didier Raoult

• Coronavirus